Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
43 authors.
Francesca Citron *Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5896-3008
Luca Cecchetto *Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9746-639X
Elisabetta GranatoDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7207-5832
I-Lin HoDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8914-710X
Zhaoliang LiuDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2074-1522
Chiara BalestrieriCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0001-7362-3530
Er-Yen YenDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2918-5419
Luigi PerelliDivision of Discovery Science, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7320-8193
Li ZhangDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7750-6427
Luis A Castillo MontanezDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5442-4349
Charles A DykeDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0007-5431-5445
Rutvi ShahDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2382-9175
Sergio AttanasioDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2576-0834
Sanjana SrinivasanTRACTION, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1439-1052
Sunetra RoyDivision of Discovery Science, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0009-2197-3286
Hyuk Jean KwonDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0000-7055-0014
Nicholas BlazaninDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0000-4171-1624
Yue ChenDivision of Discovery Science, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4699-7331
Ko-Chien ChenDivision of Discovery Science, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5480-3683
Ziheng ChenDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1918-106X
Iolanda ScognamiglioDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0276-3207
Nhung PhamDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4792-3761
Shan JiangDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2042-5298
Jing PanDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0008-7320-8060
Cecilia S LeungDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0000-3458-3417
Linghua WangDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9380-0266
Sisi GaoDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4809-1699
Alessandro CarugoTRACTION, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5182-3320
Huamin WangDivision of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2038-5863
Wantong YaoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0172-7530
Giovanni TononCenter for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0003-2973-5038
Maria Chiara BoniniExperimental Hematology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0002-0772-1674
Malgorzata Anna ZalDivision of VP, Research, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1015-3954
Collene JeterDivision of VP, Research, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9627-4529
John A TainerDivision of Discovery Science, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1659-2429
Timothy P HeffernanTRACTION, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3166-8922
Virginia GiulianiTRACTION, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2439-4986
Yonathan LissanuDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1024-5303
Giannicola GenoveseDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1392-9954
Mauro Di PilatoDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3902-7406
Andrea VialeDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4328-1044
Katharina SchlacherDivision of Discovery Science, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7226-6391
Giulio F DraettaDepartment of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5225-9610
Funding
The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2006 to 2025
$41.7M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2019 to 2023
$11.0M
Mesoscale and Nanoscale Technologies Integrated by Structures for DNA Repair Complexes (MANTIS-DRC)R35CA220430 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI John A. Tainer · 2018 to 2026
$7.6M
Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancerR01CA258917 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VIALE, ANDREA · 2021 to 2025
$2.3M
American Association for Cancer Research (AACR) 22-40-12-CITRAndrew Sabin Family FoundationCancer Prevention and Research Institute of Texas (CPRIT) RP180463Cancer Prevention and Research Institute of Texas (CPRIT) RP180813Cancer Prevention and Research Institute of Texas (CPRIT) RP190599Cancer Prevention and Research Institute of Texas (CPRIT) RP210028Cancer Prevention and Research Institute of Texas (CPRIT) RR210017Cancer Prevention and Research Institute of Texas (CPRIT) RR250083Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 28274Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 800924National Institute of Environmental Health Sciences (DEHS) 1R01ES029680National Institutes of Health (NIH) P01 CA117969-12National Institutes of Health (NIH) P50CA221707NCI NIH HHS P01 CA117969NCI NIH HHS R01 CA258917NCI NIH HHS R35 CA220430Rita Allen Foundation (RAF) fellowshipUniversity of Texas MD Anderson Cancer Center (MD Anderson) Bridge FundUniversity of Texas MD Anderson Cancer Center (MD Anderson) Pancreatic Cancer Moon Shot and PanCANUniversity of Texas MD Anderson Cancer Center (MD Anderson) start-up fundsU.S. Department of Defense (DOD) HT94252510047V Foundation for Cancer Research (VFCR) V2020-018
6 · The paper itself
Abstract
Perturbations in DNA replication can impair fork stability, resulting in cumulative DNA replication stress. As activation of the DNA stress response elicits immunomodulatory effects, understanding the cross-talk between the epigenetic control of replication fork stability and the recruitment of immune cells may represent an actionable avenue to potentiate the sensitivity of tumors to immunotherapy. In this study, we identified DPY30, a member of the histone methyltransferase WRAD/COMPASS complex, as a replication stress-specific epigenetic modifier in pancreatic ductal adenocarcinoma (PDAC). Although other WRAD components broadly regulate transcription, DPY30 distinctively promoted H3K4me3 deposition at stressed DNA replication forks to safeguard DNA replication stability without altering global gene expression. Loss of DPY30 destabilized stalled forks causing fork degradation, chromosomal instability, and inflammation without reducing cancer cell proliferation. Consequently, T-cell infiltration induced by DPY30 deficiency promoted a tumor response to immune checkpoint blockade (ICB). In patients with PDAC, high DPY30 tumor expression was associated with poorer ICB response, underscoring the potential of DPY30 as a predictive biomarker of immunotherapy response. Together, this study redefines our understanding of a replication stress-specific epigenetic code, unveiling DPY30 as a chromatin switch essential for stressed fork stability and a potential therapeutic target. SIGNIFICANCE: Loss of DPY30, a replication stress-specific epigenetic regulator that stabilizes stressed forks, promotes genomic instability, inflammation, and immunotherapy sensitivity, highlighting DPY30 as predictive biomarker and therapeutic target in pancreatic cancer. See related commentary by Thakur and Oberdoerffer, p. 2831.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. · full record | OpenQuestion